Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.44 |
| ▸ | ANPEP | P15144 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13008562 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL12604254 | 0.83 | MMP2 (0.42) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL22541603 | 0.81 | PEPD (0.43) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL15961007 | 0.81 | MMP2 (0.39) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL24004323 | 0.79 | ATM (0.53) | ALDH1A1ATMPOLB | |
| SCHEMBL2033864 | 0.79 | ATM (0.53) | ALDH1A1ATMPOLB | |
| SCHEMBL15905731 | 0.79 | ATM (0.53) | ALDH1A1ATMPOLB | |
| SCHEMBL5021550 | 0.79 | ATM (0.53) | ALDH1A1ATMPOLB | |
| SCHEMBL7892261 | 0.78 | ATM (0.39) | ATM | |
| SCHEMBL20705058 | 0.78 | ATM (0.39) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776964-B2 | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3083562-B1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | ELI LILLY AND COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| CN-105793242-A | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators | 伊莱利利公司 | 2016-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | PTGER4, PTGER1, GPR4 | ALDH1A1 2191/4885MMP2 2421/4885ANPEP 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.